Mind Medicine (MindMed)
We have no price for Mind Medicine (MindMed) since 30 April 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Mind Medicine (MindMed) vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Mind Medicine (MindMed) | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Mind Medicine (MindMed)'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $20.00
- Range
- $14.00 – $28.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 5, 2026 | -0.51 | -0.48 | −6.3% |
| Nov 6, 2025 | -0.78 | -0.52 | −50.0% |
| Jul 31, 2025 | -0.50 | -0.38 | −31.6% |
| May 8, 2025 | -0.35 | -0.36 | +2.8% |
| Mar 6, 2025 | -0.41 | -0.33 | −24.2% |
| Nov 7, 2024 | -0.27 | -0.29 | +6.9% |
| Aug 13, 2024 | -0.48 | -0.30 | −60.0% |
| May 8, 2024 | -0.60 | -0.66 | +9.1% |
News
Mind Medicine Q3 2026 Earnings PreviewSeeking Alpha · Nov 8, 2026Berkshire’s Mind-BenderYahoo Finance · Oct 16, 2026Why the world’s No. 1 fund manager has just changed its mind on bonds for the first time in six yearsMarketWatch · Oct 13, 2026Bessent urges Fed to keep ‘open mind’ on rates as AI boosts productivitySeeking Alpha · Sep 27, 2026A rare Microsoft bear warms up to the stock. Here's what changed their mindCNBC · Sep 23, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Mind Medicine (MindMed)
Is Mind Medicine (MindMed) a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Mind Medicine (MindMed) AI analysis
What does Mind Medicine (MindMed) do?
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. It is in Biotechnology.
Who are Mind Medicine (MindMed)'s competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Mind Medicine (MindMed)'s.
Prices: daily closes to Apr 30, 2026. Fundamentals: company reports via invest-like data.